NeuroQuest is developing a blood-based diagnostic test for Alzheimer's disease. The technology is based on the specific response of the immune system to a neurological injury, which is detectable in FACS analysis of whole blood.

NeuroQuest has established a US subsidiary and clinical development center at the Roper St. Francis Clinical Biotechnology Research Institute with the assistance and financial support of the South Carolina Research Authority.

The company's patent-pending technology is based on the award-winning research of Professor Michal Schwartz of the Weizmann Institute of Science. NeuroQuest has licensed the intellectual property covering this technology from Yeda (the Technology Transfer Company of the Weizmann Institute of Science) and holds an exclusive global license for its development and commercialization.